Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol versus ferric carboxymaltose safety study in iron deficiency anemia
2016-000831-41Phase 3Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Apr 2016
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in iron deficiency anemia (IDA) comparing Ferumoxytol with Ferric carboxymaltose (2 arms). Primary endpoint: Incidence of moderate to severe hypersensitivity reactions including anaphylaxis and moderate to severe hypotension. Started Apr 2016; status: completed.
02
Drugs
ferumoxytolferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2016-000831-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000831-41.